VIEWPOINT
Prescribing BiDil
Is It Black and White?
Susanne B. Haga, PhD* and
Geoffrey S. Ginsburg, MD, PhD
Center for Genomic Medicine, Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina.
Manuscript received February 21, 2006;
accepted February 21, 2006.
* Reprint requests and correspondence: Dr. Susanne B. Haga, Senior Policy Scientist, Institute for Genome Sciences & Policy, Duke University, 101 Science Drive, Box 3382, Durham, North Carolina 27708. (Email: susanne.haga{at}duke.edu).
The approval of BiDil as an adjunct treatment in self-identified blacks with heart failure raises questions regarding the underlying etiology of drug response in this target population and the ability to accurately identify patients who are most likely to benefit. Preliminary data have indicated that differences in nitric oxide synthesis between groups may account for differences in response to BiDil and genetic studies have begun to elucidate the mechanism of these differences. Until more accurate selection criteria are developed to identify patients who are most likely to benefit, both clinicians and the general public will need to consider the unique issues raised by BiDil.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | FDA = Food and Drug Administration | | HF = heart failure |
|
This article has been cited by other articles:
|
|
|
|
 
S. Kreimer
BiDil Not Widely Prescribed
DOC News,
July 1, 2007;
4(7):
23 - 23.
[Full Text]
|
|
|
|
|
|
|
R. Temple and N. L. Stockbridge
BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective
Ann Intern Med,
January 2, 2007;
146(1):
57 - 62.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
